Literature DB >> 8402650

Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract.

L F Brown1, B Berse, R W Jackman, K Tognazzi, E J Manseau, D R Senger, H F Dvorak.   

Abstract

Vascular permeability factor (VPF) is one of the most potent known inducers of microvascular hyperpermeability; in addition, it is a selective endothelial cell growth factor, hence its alternate name, vascular endothelial growth factor. VPF exerts its actions on the microvasculature by interacting with specific endothelial cell receptors. VPF is expressed by many transplantable animal tumors, by tumor cell lines in culture, and by certain normal cells in situ. The purpose of the present investigation was to determine whether and with what consistency VPF and its endothelial cell receptors are expressed in primary autochthonous human tumor of gastrointestinal tract origin, as determined by in situ hybridization and immunohistochemistry. Twenty-one primary adenocarcinomas (17 colon, 2 stomach, 1 small bowel, and 1 pancreas) were studied. The malignant epithelial cells expressed VPF mRNA strongly, in contrast to normal epithelium, hyperplastic polyps, and adenomas, which expressed little or no VPF mRNA. VPF expression was further increased in tumor cells immediately adjacent to zones of tumor necrosis; in such areas, occasional stromal cells also expressed VPF mRNA. In the ten colon carcinomas studied, tumor cells stained for VPF protein by immunohistochemistry. The endothelial cells of nearby stromal blood vessels also stained for VPF by immunohistochemistry and in addition expressed mRNAs encoding the VPF receptors flt-1 and kdr as determined by in situ hybridization. Endothelial cells away from the tumor did not stain for VPF and no definite mRNA expression for flt-1 or kdr was detected by in situ hybridization. The ganglion cells of the myenteric plexus of normal bowel expressed VPF mRNA and protein. These data indicate that primary autochthonous human tumors of gastrointestinal origin regularly express both VPF mRNA and VPF protein and that adjacent stromal vessels express mRNAs for both known VPF receptors. VPF is likely to contribute to tumor growth by promoting angiogenesis and stroma formation, both directly, through its action as an endothelial cell growth factor, and indirectly, by increasing vascular permeability, thereby leading to plasma protein extravasation, fibrin deposition, and the eventual replacement of the resulting matrix with vascularized stroma.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8402650

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  123 in total

1.  Expression of VEGF(121) in gastric carcinoma MGC803 cell line.

Authors:  Jun-Tian Xue; Jian Wu; Lin Meng; Zhi-Wei Dong; Cheng-Chao Shou
Journal:  World J Gastroenterol       Date:  2000-04       Impact factor: 5.742

Review 2.  Sonic Hedgehog in pancreatic cancer: from bench to bedside, then back to the bench.

Authors:  David E Rosow; Andrew S Liss; Oliver Strobel; Stefan Fritz; Dirk Bausch; Nakul P Valsangkar; Janivette Alsina; Birte Kulemann; Joo Kyung Park; Junpei Yamaguchi; Jennifer LaFemina; Sarah P Thayer
Journal:  Surgery       Date:  2012-07-06       Impact factor: 3.982

3.  Dynamic contrast-enhanced magnetic resonance imaging reveals stress-induced angiogenesis in MCF7 human breast tumors.

Authors:  E Furman-Haran; R Margalit; D Grobgeld; H Degani
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

4.  Implications of human macrophage metalloelastase and vascular endothelial growth factor gene expression in angiogenesis of hepatocellular carcinoma.

Authors:  M J Gorrin-Rivas; S Arii; A Mori; Y Takeda; M Mizumoto; M Furutani; M Imamura
Journal:  Ann Surg       Date:  2000-01       Impact factor: 12.969

5.  Hypoxia-induced expression of vascular endothelial growth factor by retinal glial cells promotes in vitro angiogenesis.

Authors:  Y Hata; K Nakagawa; T Ishibashi; H Inomata; H Ueno; K Sueishi
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

6.  Prognostic and predictive value of serum vascular endothelial growth factor (VEGF) in squamous cell carcinoma of the head and neck.

Authors:  Bijan Khademi; Mehdi Soleimanpour; Abbas Ghaderi; Mohammad Mohammadianpanah
Journal:  Oral Maxillofac Surg       Date:  2013-03-03

7.  A phase I surrogate endpoint study of SU6668 in patients with solid tumors.

Authors:  Henry Q Xiong; Roy Herbst; Silvana C Faria; Catherine Scholz; Darren Davis; Edward F Jackson; Timothy Madden; David McConkey; Marshall Hicks; Kenneth Hess; Chusilp Arthur Charnsangavej; James L Abbruzzese
Journal:  Invest New Drugs       Date:  2004-11       Impact factor: 3.850

8.  Strong expression of kinase insert domain-containing receptor, a vascular permeability factor/vascular endothelial growth factor receptor in AIDS-associated Kaposi's sarcoma and cutaneous angiosarcoma.

Authors:  L F Brown; K Tognazzi; H F Dvorak; T J Harrist
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

Review 9.  Similarities and differences between the vascular endothelial growth factor (VEGF) splice variants.

Authors:  G Neufeld; T Cohen; H Gitay-Goren; Z Poltorak; S Tessler; R Sharon; S Gengrinovitch; B Z Levi
Journal:  Cancer Metastasis Rev       Date:  1996-06       Impact factor: 9.264

10.  [Bevacizumab in the first-line therapy of advanced NSCLC].

Authors:  Norbert Hasenöhrl
Journal:  Wien Med Wochenschr       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.